Pulmonx has announced final results of its Chartis multi-centre study

Pulmonx has just announced final results of its Chartis multi-centre study, presented at the European Respiratory Society’s 2011 Congress.

This definitive data confirms that use of the Chartis® Pulmonary Assessment System to plan Zephyr® Endobronchial Valve (EBV) treatments is the key to successful EBV treatment of emphysema.The Chartis assessment quickly and reliably provides regional lung information to allow a physician to plan EBV treatment in a way that maximises the potential benefit to the patient. This is a key breakthrough that will enable physicians to offer this highly effective and minimally invasive treatment option to many more patients, with significant benefit to the majority treated.

“Using the Chartis System to plan EBV treatment can result in very significant benefits for emphysema patients, in terms of improvement in lung function and quality of life,” said Professor Felix Herth, MD, PhD., FCCP, Chairman and Head of Pneumology and Respiratory Care at Thoraxklinik, University of Heidelberg, Germany. “I really believe that we have the opportunity to expand this therapy, now that we have proven the effectiveness of the Chartis System and EBV in reducing hyperinflation, and I would expect to see Chartis and EBV treatment become a standard-ofcare in the management of emphysema,” he continued. The Chartis Study enrolled 97 emphysema patients, some of who would not have been treated under earlier study protocols. All patients underwent a Chartis assessment, followed by treatment with Zephyr EBV in one single lobe of the lung. The Chartis System accurately predicted response in 3 out of 4 patients. And patients who responded per Chartis prediction experienced significant improvements in their lung function, exercise tolerance, and quality of life.“The Chartis Study data has clearly shown that EBV therapy plays an important role in managing emphysema” said Dirk-Jan Slebos, MD, Ph.D., Department of Pulmonary Diseases, University Medical Center, Groningen, and co-lead investigator. “We have patients responding in ways that can only be called “life-changing”. Finally, we have something that can truly make a difference for the patient

Source: pulmonx

Share your thoughts

Your email address will not be published. Required fields are marked *